Skip to main content

Advertisement

SpringerLink
Log in

Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population

  • Interventional Oncology (DC Madoff, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Venous thromboembolic disease causes significant mortality and morbidity in the oncologic patient population. Recently, minimally invasive endovascular technologies have been developed as an adjunct to antithrombotic therapy for the management of DVT and PE. The current and potential roles for endovascular treatment of cancer-associated venous thromboembolism (VTE) will be reviewed in this article.

Recent Findings

The recent NCCN guidelines recommend endovascular therapy in patients eligible for therapeutic anticoagulation who present with life-, organ-, or limb-threatening thrombosis. However, symptomatic non-life-threatening VTE can negatively affect QOL and physical function, both of which have prognostic implications in the cancer population. Endovascular therapies have been shown to improve physical function and QOL in prospective trials performed in a non-oncologic patient population as well as small retrospective studies in the cancer population.

Summary

In addition to treating life- and limb-threatening thrombosis, endovascular therapy for VTE can improve QOL and physical function in comparison to anticoagulation alone. Prospective trials are warranted to assess the benefit of endovascular therapy for quality of life-years, performance status, and overall survival in the oncologic patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl):S495-501.

    Article  PubMed  Google Scholar 

  2. Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636–61.

    Article  PubMed  Google Scholar 

  3. Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev. 2014;28(6):221–6.

    Article  CAS  PubMed  Google Scholar 

  4. Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(11):1245–8.

    Article  PubMed  Google Scholar 

  5. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers. 2018;10(10):380.

  7. Trujillo-Santos J, Herrera S, Page MA, Soto MJ, Raventós A, Sánchez R, et al. Predicting adverse outcome in outpatients with acute deep vein thrombosis. findings from the RIETE Registry. J Vasc Surg. 2006;44(4):789–93.

  8. Gupta R, Ammari Z, Dasa O, Ruzieh M, Burlen JJ, Shunnar KM, et al. Long-term mortality after massive, submassive, and low-risk pulmonary embolism. Vasc Med Lond Engl. 2020;25(2):141–9.

    Article  Google Scholar 

  9. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–8.

    Article  CAS  PubMed  Google Scholar 

  10. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64.

    Article  PubMed  Google Scholar 

  11. •• Marin-Barrera L, Muñoz-Martin AJ, Rios-Herranz E, Garcia-Escobar I, Beato C, Font C, et al. A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: quality of life in cancer (Qca) study. Cancers. 2019;12(1). Prospective case control study demonstrating the QOL impact of VTE in the cancer population.

  12. • Mierzynska J, Piccinin C, Pe M, Martinelli F, Gotay C, Coens C, et al. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. Lancet Oncol. 2019;20(12):e685–98. Meta-analysis of patient-reported outcomes in cancer trials, which determined that physical function and global QOL are important predictors of overall survival.

  13. Enden T, Haig Y, Kløw N-E, Slagsvold C-E, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet Lond Engl. 2012;379(9810):31–8.

    Article  Google Scholar 

  14. Haig Y, Enden T, Grøtta O, Kløw N-E, Slagsvold C-E, Ghanima W, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016;3(2):e64-71.

    Article  PubMed  Google Scholar 

  15. • Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240–52. Highly-cited RCT comparing PCDT to AC alone to prevent PTS in patients with iliofemoral DVT. While PCDT did not reduce the incidence of PTS, it did reduce severity. The subgroup analyses are particularly relevant to the cancer population.

  16. Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP, Strijkers RHW, de Smet AAEA, Tick LW, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol. 2020;7(1):e40-9.

    Article  PubMed  Google Scholar 

  17. Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv. 2015;8(10):1382–92.

    Article  PubMed  Google Scholar 

  18. Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129(4):479–86.

    Article  PubMed  Google Scholar 

  19. Kuo WT, Banerjee A, Kim PS, DeMarco FJ, Levy JR, Facchini FR, et al. Pulmonary embolism response to fragmentation, embolectomy, and catheter thrombolysis (PERFECT): initial results from a prospective multicenter registry. Chest. 2015;148(3):667–73.

    Article  PubMed  Google Scholar 

  20. Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC Cardiovasc Interv. 2018;11(14):1401–10.

    Article  PubMed  Google Scholar 

  21. • Rabellino M, Moltini P, Di Caro V, García-Mónaco R. Symptomatic iliofemoral and iliocaval venous thrombosis in patients with cancer: endovascular treatment. Vasc Endovascular Surg. 2018;52(8):602–6. Small cohort study demonstrating safety and efficacy of endovascular therapy in the cancer-associated VTE.

  22. • O’Sullivan GJ, Waldron D, Mannion E, Keane M, Donnellan PP. Thrombolysis and iliofemoral vein stent placement in cancer patients with lower extremity swelling attributed to lymphedema. J Vasc Interv Radiol JVIR. 2015;26(1):39–45. Largest study to date evaluating symptomatic improvement associated with endovacular therapy for cancer-associated DVT.

  23. Drabkin MJ, Bajwa R, Perez-Johnston R, Bryce Y, Boas FE, Siegelbaum R, et al. Anticoagulation reduces iliocaval and iliofemoral stent thrombosis in patients with cancer stented for nonthrombotic venous obstruction. J Vasc Surg Venous Lymphat Disord. 2021;9(1):88–94.

    Article  PubMed  Google Scholar 

  24. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019 24;133(4):291–8.

  25. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780–5.

    CAS  PubMed  Google Scholar 

  27. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–86.

    Article  CAS  PubMed  Google Scholar 

  28. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53.

    Article  CAS  PubMed  Google Scholar 

  29. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost. 2021;121(5):616–24.

  30. McBane RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost JTH. 2020;18(2):411–21.

    Article  CAS  PubMed  Google Scholar 

  31. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–607.

  32. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24.

    Article  CAS  PubMed  Google Scholar 

  33. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(20):2017–23.

  34. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

    Article  PubMed  Google Scholar 

  35. van der Wall SJ, Klok FA, den Exter PL, Barrios D, Morillo R, Cannegieter SC, et al. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost JTH. 2017;15(1):74–9.

    Article  PubMed  Google Scholar 

  36. Lee AYY. When can we stop anticoagulation in patients with cancer-associated thrombosis? Blood. 2017;130(23):2484–90.

  37. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983;13(3):334–6.

    Article  CAS  PubMed  Google Scholar 

  38. Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res. 2009;29(10):4309–13.

    PubMed  Google Scholar 

  39. Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015;124(1):87–94.

    Article  CAS  PubMed  Google Scholar 

  40. Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg. 1987;66(3):357–8.

    Article  CAS  PubMed  Google Scholar 

  41. Scott M. Spontaneous intracerebral hematoma caused by cerebral neoplasms. Report of eight verified cases. J Neurosurg. 1975;42(3):338–42.

  42. Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015;126(4):494–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73(2):493–8.

    Article  CAS  PubMed  Google Scholar 

  44. Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu W-J, et al. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. 2012;22(4):310–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(5):496–520.

  46. Mantha S, Miao Y, Wills J, Parameswaran R, Soff GA. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis. 2017;43(4):514–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology. 1994;191(2):487–94.

    Article  CAS  PubMed  Google Scholar 

  48. Sista AK, Vedantham S, Kaufman JA, Madoff DC. Endovascular interventions for acute and chronic lower extremity deep venous disease: state of the art. Radiology. 2015;276(1):31–53.

    Article  PubMed  Google Scholar 

  49. Thukral S, Vedantham S. Catheter-based therapies and other management strategies for deep vein thrombosis and post-thrombotic syndrome. J Clin Med. 2020;9(5):1439.

  50. Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol JVIR. 2004;15(4):347–52.

    Article  PubMed  Google Scholar 

  51. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol JVIR. 2009;20(11):1431–40.

    Article  PubMed  Google Scholar 

  52. Haupt B, Merkle F, Dreizler T, Falk V, Starck C. Technical implementation of percutaneous thrombus aspiration using the AngioVac system. Perfusion. 2020;13:267659120946734.

    Google Scholar 

  53. Wible BC, Buckley JR, Cho KH, Bunte MC, Saucier NA, Borsa JJ. Safety and efficacy of acute pulmonary embolism treated via large-bore aspiration mechanical thrombectomy using the Inari FlowTriever Device. J Vasc Interv Radiol JVIR. 2019;30(9):1370–5.

    Article  PubMed  Google Scholar 

  54. Benarroch-Gampel J, Pujari A, Aizpuru M, Rajani RR, Jordan WD, Crawford R. Technical success and short-term outcomes after treatment of lower extremity deep vein thrombosis with the ClotTriever system: a preliminary experience. J Vasc Surg Venous Lymphat Disord. 2020;8(2):174–81.

    Article  PubMed  Google Scholar 

  55. Lopez R, DeMartino R, Fleming M, Bjarnason H, Neisen M. Aspiration thrombectomy for acute iliofemoral or central deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2019;7(2):162–8.

    Article  PubMed  Google Scholar 

  56. Avgerinos ED, Abou Ali A, Toma C, Wu B, Saadeddin Z, McDaniel B, et al. Catheter-directed thrombolysis versus suction thrombectomy in the management of acute pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2019;7(5):623–8.

    Article  PubMed  Google Scholar 

  57. O’Sullivan GJ, Semba CP, Bittner CA, Kee ST, Razavi MK, Sze DY, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol JVIR. 2000;11(7):823–36.

    Article  PubMed  Google Scholar 

  58. Epelboym Y, Stecker MS, Fan C-M, Killoran TP, Rabkin DJ, Schenker MP. Treatment of malignant inferior vena cava obstruction with Gianturco-Rosch-Z stents: a single center 13-year experience. Clin Imaging. 2020;59(2):95–9.

    Article  PubMed  Google Scholar 

  59. Devcic Z, Techasith T, Banerjee A, Rosenberg JK, Sze DY. Technical and anatomic factors influencing the success of inferior vena caval stent placement for malignant obstruction. J Vasc Interv Radiol JVIR. 2016;27(9):1350-1360.e1.

    Article  PubMed  Google Scholar 

  60. Razavi MK, Black S, Gagne P, Chiacchierini R, Nicolini P, Marston W, et al. Pivotal study of endovenous stent placement for symptomatic iliofemoral venous obstruction. Circ Cardiovasc Interv. 2019;12(12):e008268.

  61. Tang TY, Lim MH, Damodharan K, Yap CJ, Lee SQ, Yap HY, et al. Use of the VENOVOTM and Sinus ObliquusTM venous stents in the treatment of non-thrombotic or post-thrombotic iliac vein lesions - short-term results from a multi-centre Asian cohort. Phlebology. 2021;36(1):70–8.

    Article  CAS  PubMed  Google Scholar 

  62. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–830.

    Article  PubMed  Google Scholar 

  63. Vedantham S, Millward SF, Cardella JF, Hofmann LV, Razavi MK, Grassi CJ, et al. Society of Interventional Radiology position statement: treatment of acute iliofemoral deep vein thrombosis with use of adjunctive catheter-directed intrathrombus thrombolysis. J Vasc Interv Radiol JVIR. 2006;17(4):613–6.

    Article  PubMed  Google Scholar 

  64. •• Kahn SR, Julian JA, Kearon C, Gu C-S, Cohen DJ, Magnuson EA, et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2020;8(1):8-23.e18. Subgroup analysis of the ATTRACT trial demonstrating improvement in global and VTE specific QOL in patients treated with PCDT for symptomatic iliofemoral venous obstruction.

  65. Weinberg I, Vedantham S, Salter A, Hadley G, Al-Hammadi N, Kearon C, et al. Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: results from the ATTRACT Multicenter Randomized Trial. Vasc Med Lond Engl. 2019;24(5):442–51.

    Article  Google Scholar 

  66. •• Comerota AJ, Kearon C, Gu C-S, Julian JA, Goldhaber SZ, Kahn SR, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation. 2019;139(9):1162–73. Subgroup analysis of the ATTRACT trial demonstrating early improvements in physical function in patients undergoing PCDT for symptomatic iliofemoral DVT.

  67. Janakiram M, Sullivan M, Shcherba M, Guo S, Billett HH. A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis. Thrombosis. 2013;2013:247913.

  68. Dudzinski DM, Giri J, Rosenfield K. Interventional treatment of pulmonary embolism. Circ Cardiovasc Interv. 2017;10(2).

  69. Sista AK, Kuo WT, Schiebler M, Madoff DC. Stratification, imaging, and management of acute massive and submassive pulmonary embolism. Radiology. 2017;284(1):5–24.

    Article  PubMed  Google Scholar 

  70. Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383–9.

    Article  PubMed  Google Scholar 

  71. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Kline JA, Roy P-M, Than MP, Hernandez J, Courtney DM, Jones AE, et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE-C tool. Thromb Res. 2012;129(5):e194-199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Carmona-Bayonas A, Jiménez-Fonseca P, Font C, Fenoy F, Otero R, Beato C, et al. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Br J Cancer. 2017;116(8):994–1001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Perez-Johnston R, Plodkowski AJ, Halpenny DF, Hayes SA, Capanu M, Araujo-Filho J a. B, et al. Perfusion defects on dual-energy CTA in patients with suspected pulmonary embolism correlate with right heart strain and lower survival. Eur Radiol. 2020

  75. •• Piazza G, Sterling KM, Tapson VF, Ouriel K, Sharp ASP, Liu P-Y, et al. One-year echocardiographic, functional, and quality of life outcomes after ultrasound-facilitated catheter-based fibrinolysis for pulmonary embolism. Circ Cardiovasc Interv. 2020;13(8):e009012. USAT for intermediate risk PE demonstrated improvement in clinical outcomes and QOL in non-cancer patients. While a subgroup analysis of a larger trial, these outcomes are relevant to the cancer population, and need validation in an oncologic cohort.

  76. Kim HS, Preece SR, Black JH, Pham LD, Streiff MB. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg. 2008;47(2):388–94.

    Article  PubMed  Google Scholar 

  77. Yoon WJ, Halandras P, Aulivola B, Crisostomo P. Malignancy does not affect outcomes of pharmacomechanical thrombolysis in acute symptomatic iliofemoral deep vein thrombosis. Ann Vasc Surg. 2018;51:234–8.

    Article  PubMed  Google Scholar 

  78. Brailovsky Y, Yeung H-M, Lakhter V, Zack CJ, Zhao H, Bashir R. In-hospital outcomes of catheter-directed thrombolysis versus anticoagulation in cancer patients with proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2020;8(4):538-544.e3.

    Article  PubMed  Google Scholar 

  79. Sista AK, Friedman OA, Dou E, Denvir B, Askin G, Stern J, et al. A pulmonary embolism response team’s initial 20 month experience treating 87 patients with submassive and massive pulmonary embolism. Vasc Med Lond Engl. 2018;23(1):65–71.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sirish A. Kishore & Raazi Bajwa

  2. Department of Radiology, Stanford University, Palo Alto, CA, USA

    Sirish A. Kishore

  3. Department of Medicine, Division of Hematologic/Oncology, Columbia University Medical Center, New York, NY, USA

    Layla Van Doren

  4. Department of Medicine, Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Cy Wilkins

  5. Department of Interventional Radiology, Galway University Hospital, Galway, Ireland

    Gerard J. O’Sullivan

Authors
  1. Sirish A. Kishore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raazi Bajwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Layla Van Doren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cy Wilkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerard J. O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sirish A. Kishore.

Ethics declarations

Competing Interests

S.K. is a paid advisor for Inari Medical and receives research funds from Boston Scientific. GOS is a paid speaker for Boston Scientific, BD, Medtronic, Cook Medical, and a paid advisor for Mermaid Medical, Whiteswell, Surmodics, Merit Medical, Marvao Medical, and holds equity in Marvao Medical. RB, CW, and LVD report no conflicts of interest.

Human and Animal Rights

All reported experiments/studies with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Interventional Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kishore, S.A., Bajwa, R., Van Doren, L. et al. Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population. Curr Oncol Rep 24, 351–362 (2022). https://doi.org/10.1007/s11912-022-01191-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-022-01191-6

Keywords

Search

Navigation